@infogm.bsky.social
@infogm.bsky.social
@biorasi.bsky.socialNEW @biorasi.bsky.social Article - Proof Over Promises: bit.ly/4yMyOJ6
Why do programs stall between #firstinhuman and #proofofconcept? Learn how decision-ready execution builds an important bridge to keep #clinicaltrials moving.
@pharmalot.bsky.social
@newsen.bsky.socialEmerging Biotech Firms Accelerate Drug Development with Veeva Basics Implementation #USA #Veeva_Systems #biotech #Drug_Development #Pleasanton
@pharmaphorum.bsky.socialThere's a fairly buoyant operating environment in the #US #biotech sector at the moment, fuelled by an improving #financing climate, but not all companies are thriving.
@proteintech.bsky.socialSpeaker Spotlight: Eric Haas, MEng, Founder/CEO of Ionic Cytometry Solutions, built deep expertise in mass cytometry running the CyTOF core at Dana-Farber before founding his own company.
Hear his story at our upcoming webinar: https://bit.ly/4hIEX2V
@carlus-2024.bsky.socialOctober 7, 2026
👉 What if better understanding children’s livers could help us better treat their diseases?
🙂 Another encouraging news from Groupe UIG.
Read: www.uhn.ca/corporate/Ne...
#Biotech #LifeSciences #SingleCell #Genomics #PediatricHealth #LiverDisease #PrecisionMedicine
@carlus-2024.bsky.social7 octobre 2026
👉 Et si mieux comprendre le foie des enfants permettait de mieux traiter leurs maladies?
🙂 Une autre nouvelle encourageante du Groupe UIG.
Lire: www.uhn.ca/corporate/Ne...
#Biotech #LifeSciences #SingleCell #Genomics #PediatricHealth #LiverDisease
@biotechstockdaily.bsky.socialSurrozen receives FDA clearance to begin the Phase 1b/2a DUET trial of SZN-8141 in diabetic macular edema.
#Biotech #Biotechnology #Health #Trial
Disclaimer: This is NOT a financial advice.
@thedailyfathom.bsky.socialBIOTECH · ArriVent's lung cancer drug fails key trial, stock halves
Firmonertinib missed its main goal in a pivotal lung cancer trial, and ArriVent's stock lost more than half its value within hours.
@learnbiotech.bsky.socialIncorporating Probability of Success (PoS) is a unique aspect of #biotech valuation investors must be aware of.
It tries to factor development risk into revenue and cost assumptions.
Here is a table of PoS values:
@drtimos.bsky.social🧠 Competitive Insights for #BioPharma and #HealthTech 🚀
#LucidQuest arms #pharma & #biotech with real-time intel to outpace rivals from R&D to market.
📩 [email protected] or http://dlvr.it/TVpnLV
#CompetitiveIntelligence #Strategy #MarketAccess
@drtimos.bsky.socialSignal or noise? > Our top picks for ESGCT 2026 - RegMedNet >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #pharmaceutical #pharma #healthcare
@4040rec.bsky.social
@biotechstockdaily.bsky.socialNovartis licenses Abogen's mRNA-encoded T-cell engager ABO2203 for $575M upfront. Option terms, royalty rates, and the milestone split were not disclosed.
@uapdrop.bsky.socialPolarity links a reported Russian pneumonic plague lab incident, a FlyDubai hijack claim, and Regulus prophecy to a broader UAP, occult, and disclosure thread—testing official narratives and tracing biotech and geopolitics. #UAP #Disclosure #Biotech
@drtimos.bsky.socialSignal or noise? > Epcoritamab in DLBCL: beyond the 0.49 >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #biotech #healthcare #pharmaceutical
@sugataai.bsky.socialPopular weight-loss drugs might do more than just shed pounds—they could actually melt away the years by slowing our biological aging. #Biotech sugataai.com/blog/weight-...
@desnips.nlForbion haalt recordbedrag van 2,3 miljard euro op voor biotechmedicijnen
@quartzmedia.bsky.socialEurope's biggest biotech VC just raised $2.6B — in a tough market #Biotech #VentureCapital